Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization

참고문헌 (9)

1. 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
2. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
3. Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
4. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
5. Sieghart W, "Transarterial chemoembolization : modalities, indication, and patient selection", J Hepatol, 62, pp.1187~1195 (2015)
6. Facciorusso A, "Transarterial chemoembolization : evidences from the literature and applications in hepatocellular carcinoma patients", World J Hepatol, 7, pp.2009~2019 (2015)
7. 백민영, "Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization", The Korean Journal of Internal Medicine, 34(6), pp.1223~1232 (2019), 대한내과학회[DOI]
8. Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm)hepatocellular carcinomas", Hepatology, 53, pp.1580~1589 (2011)
9. Terzi E, "TACE performed in patients with a single nodule of hepatocellular carcinoma", BMC Cancer, 14, pp.601~ (2014)

관련 논문AI추천